Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600645'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -261.62 Med: 52.75 Max: 6793.92
Current: 33.91
During the past 13 years, the highest EV-to-EBITDA of Zhongyuan Union Cell & Gene Engineering was 6793.92. The lowest was -261.62. And the median was 52.75.
SHSE:600645's EV-to-EBITDA is ranked worse than 74.26% of 404
companies
in the Biotechnology industry
Industry Median: 13.02
vs SHSE:600645: 33.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhongyuan Union Cell & Gene Engineering's PE Ratio (TTM) for today is calculated as:
Zhongyuan Union Cell & Gene Engineering's share price for today is ¥17.78.
Zhongyuan Union Cell & Gene Engineering's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering EV-to-EBITDA Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering EV-to-EBITDA vs Biotechnology Industry
Zhongyuan Union Cell & Gene Engineering's current Enterprise Value is ¥6,614 Mil.
Zhongyuan Union Cell & Gene Engineering's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥195 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a EV-to-EBITDA of 33.91 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zhongyuan Union Cell & Gene Engineering. This is 36% below median its historical median of 52.75. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #300 out of 404 companies in the Biotechnology industry, placing it in the top 74.3%.
Is Zhongyuan Union Cell & Gene Engineering's EV-to-EBITDA too high?
Zhongyuan Union Cell & Gene Engineering's current EV-to-EBITDA of 33.91 is 36% below median its 10-year median of 52.75. The Biotechnology industry median EV-to-EBITDA is 13.02. Zhongyuan Union Cell & Gene Engineering's value of 33.91 is 160.4% above this industry median. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #300 out of 404 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #300 out of 404 companies for EV-to-EBITDA. This places Zhongyuan Union Cell & Gene Engineering in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. Zhongyuan Union Cell & Gene Engineering's value of 33.91 is 160.4% above this benchmark. While the company's 10-year median is 52.75 vs. the industry median of 13.02, Zhongyuan Union Cell & Gene Engineering has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhongyuan Union Cell & Gene Engineering's current EV-to-EBITDA of 33.91 is 160.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zhongyuan Union Cell & Gene Engineering. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current EV-to-EBITDA is 33.91, which is 36% below median its own 10-year median of 52.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.05, compared to a current price of ¥17.78 — trading 15.5% below its estimated fair value. The current EV-to-EBITDA is 33.91, which is 36% below median its 10-year median of 52.75 and 160.4% above the Biotechnology industry median of 13.02. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current EV-to-EBITDA is 33.91 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued.
The current stock price of ¥17.78 is trading 15.5% below its estimated GF Value™ of ¥21.05.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:600645:
EV-to-EBITDA: 33.91 (36% below median its 10-year median of 52.75)
GF Value™: ¥21.05 vs. price of ¥17.78 (15.5% below fair value)
Industry Position: 160.4% above the Biotechnology median (#300 of 404)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
65GF Score
Get the complete analysis for SHSE:600645
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
